Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis
Michael H. Le, Yee Hui Yeo, Xiaohe Li, et al.
Clinical Gastroenterology and Hepatology (2021) Vol. 20, Iss. 12, pp. 2809-2817.e28
Closed Access | Times Cited: 465

Showing 26-50 of 465 citing articles:

NAFLD/MASLD and the Gut–Liver Axis: From Pathogenesis to Treatment Options
Natalia G. Vallianou, Dimitris Kounatidis, Sotiria Psallida, et al.
Metabolites (2024) Vol. 14, Iss. 7, pp. 366-366
Open Access | Times Cited: 18
Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
Eugene Han, Byung‐Wan Lee, Eun Seok Kang, et al.
Metabolism (2024) Vol. 152, pp. 155789-155789
Closed Access | Times Cited: 17
"Evolving epidemiology of HCC in Spain"
Margarita Sala, Sonia Pascual, Montserrat Roca, et al.
JHEP Reports (2025), pp. 101336-101336
Open Access | Times Cited: 2
The growing range of complications of diabetes mellitus
Peter Shane Hamblin, Anthony Russell, Stella Talic, et al.
Trends in Endocrinology and Metabolism (2025)
Closed Access | Times Cited: 1
Associations between systemic inflammatory biomarkers and metabolic dysfunction associated steatotic liver disease: a cross-sectional study of NHANES 2017–2020
Xin Qiu, Shuang Shen, Nizhen Jiang, et al.
BMC Gastroenterology (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 1
The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease
Cheng Han Ng, Kai En Chan, Yip Han Chin, et al.
Clinical and Molecular Hepatology (2022) Vol. 28, Iss. 3, pp. 565-574
Open Access | Times Cited: 64
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis
Rohit Loomba, Daniel Q. Huang, Arun J. Sanyal, et al.
Gut (2022) Vol. 72, Iss. 3, pp. 581-589
Open Access | Times Cited: 60
AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD
Grazia Pennisi, Marco Enea, Alessandra Pandolfo, et al.
Clinical Gastroenterology and Hepatology (2022) Vol. 21, Iss. 5, pp. 1293-1302.e5
Closed Access | Times Cited: 57
Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name
Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen
Clinical and Molecular Hepatology (2022) Vol. 28, Iss. 4, pp. 790-801
Open Access | Times Cited: 55
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis
Stephen A. Harrison, Peter Ruane, B. Freilich, et al.
JHEP Reports (2022) Vol. 5, Iss. 1, pp. 100563-100563
Open Access | Times Cited: 53
Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study
Sara Volpe, Giuseppe Lisco, Margherita Fanelli, et al.
Nutrients (2022) Vol. 14, Iss. 21, pp. 4673-4673
Open Access | Times Cited: 48
Mortality and Liver-Related Events in Lean Versus Non-Lean Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis
Jane Ha, Sun Young Yim, Raffi Karagozian
Clinical Gastroenterology and Hepatology (2022) Vol. 21, Iss. 10, pp. 2496-2507.e5
Open Access | Times Cited: 45
Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality
Cheng Han Ng, Zhen Yu Wong, Nicholas Chew, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 42
Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation
Amedeo Lonardo, Alessandro Mantovani, Salvatore Petta, et al.
Nature Reviews Endocrinology (2022) Vol. 18, Iss. 10, pp. 638-650
Closed Access | Times Cited: 40
Exercise in the Management of Metabolic-Associated Fatty Liver Disease (MAFLD) in Adults: A Position Statement from Exercise and Sport Science Australia
Shelley E. Keating, Angelo Sabag, Kate Hallsworth, et al.
Sports Medicine (2023) Vol. 53, Iss. 12, pp. 2347-2371
Open Access | Times Cited: 33
Management of metabolic-associated fatty liver disease: The diabetology perspective
Mohammad Sadiq Jeeyavudeen, Shahanas K A Khan, Sherouk Fouda, et al.
World Journal of Gastroenterology (2023) Vol. 29, Iss. 1, pp. 126-143
Open Access | Times Cited: 32
Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease
Leke Wiering, Pallavi Subramanian, Linda Hammerich
Cellular and Molecular Gastroenterology and Hepatology (2023) Vol. 15, Iss. 6, pp. 1277-1292
Open Access | Times Cited: 32
Perspectives on the Underlying Etiology of HCC and Its Effects on Treatment Outcomes
Takanori Ito, Mindie H. Nguyen
Journal of Hepatocellular Carcinoma (2023) Vol. Volume 10, pp. 413-428
Open Access | Times Cited: 32
Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes
Grazia Pennisi, Marco Enea, Vincenzo Falco, et al.
Hepatology (2023) Vol. 78, Iss. 1, pp. 195-211
Open Access | Times Cited: 32
Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
Wayne Eskridge, Donna R. Cryer, Jörn M. Schattenberg, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 19, pp. 6216-6216
Open Access | Times Cited: 31
LncRNA and circRNA in Patients with Non-Alcoholic Fatty Liver Disease: A Systematic Review
Qingmin Zeng, Changhai Liu, Dongbo Wu, et al.
Biomolecules (2023) Vol. 13, Iss. 3, pp. 560-560
Open Access | Times Cited: 28
The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
Christine R. Andreasen, Andreas Andersen, Tina Vilsbøll
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1846-1858
Open Access | Times Cited: 26
The Effects of Eight Weeks’ Very Low-Calorie Ketogenic Diet (VLCKD) on Liver Health in Subjects Affected by Overweight and Obesity
Roberta Rinaldi, Sara De Nucci, Fabio Castellana, et al.
Nutrients (2023) Vol. 15, Iss. 4, pp. 825-825
Open Access | Times Cited: 24
Sarcopenia Among Patients With Nonalcoholic Fatty Liver Disease (NAFLD) Is Associated With Advanced Fibrosis
Michael Harring, Pegah Golabi, James M. Paik, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 21, Iss. 11, pp. 2876-2888.e5
Closed Access | Times Cited: 24
New anti-diabetic agents for the treatment of non-alcoholic fatty liver disease: a systematic review and network meta-analysis of randomized controlled trials
Tanawan Kongmalai, Varalak Srinonprasert, Thunyarat Anothaisintawee, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 24

Scroll to top